Skip to Content

LIQ861 FDA Approval Status

Last updated by Judith Stewart, BPharm on Jan 30, 2020.

FDA Approved: No
Brand name: LIQ861
Generic name: treprostinil
Dosage form: Inhalation Powder
Company: Liquidia Technologies, Inc.
Treatment for: Pulmonary Arterial Hypertension (PAH)

LIQ861 (treprostinil) is an investigational inhaled dry powder formulation of treprostinil in development for the treatment of pulmonary arterial hypertension (PAH).

Development Timeline for LIQ861

DateArticle
May 10, 2021Liquidia Resubmits New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
Nov 25, 2020Liquidia Receives Complete Response Letter from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
Apr  8, 2020Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension
Jan 27, 2020Liquidia Submits New Drug Application for LIQ861 (treprostinil) Inhalation Powder to FDA for the Treatment of Pulmonary Arterial Hypertension (PAH)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.